Back to top
more

Pacira BioSciences (PCRX)

(Delayed Data from NSDQ)

$30.33 USD

30.33
717,143

-0.13 (-0.43%)

Updated May 31, 2024 04:00 PM ET

After-Market: $30.34 +0.01 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for PCRX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

1 item in cart

View Cart/Checkout

Pacira BioSciences, Inc. [PCRX]

Reports for Purchase

Showing records 501 - 520 ( 720 total )

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 501

08/21/2015

Company Report

Pages: 7

Price: 24.95

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 502

08/19/2015

Daily Note

Pages: 6

July Symphony Health Estimate for EXPAREL Sales Increased Over June and Appears On-Track to Us; Reiterate OUTPERFORM and $106 Price Target.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 503

08/19/2015

Daily Note

Pages: 6

July Symphony Health Estimate for EXPAREL Sales Increased Over June and Appears On-Track to Us; Reiterate OUTPERFORM and $106 Price Target.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 504

07/30/2015

Company Report

Pages: 8

Q2 Financials Missed but Positive Outlook for EXPAREL Sales

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 505

07/28/2015

Company Report

Pages: 7

Price: 24.95

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 506

07/24/2015

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of July 27

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 507

07/22/2015

Company Report

Pages: 8

Q2 Preview: Symphony Health June Estimate Suggests to Us That Q2 EXPAREL Sales Are Close to Consensus

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 508

07/17/2015

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of July 20

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 509

07/01/2015

Industry Report

Pages: 44

July and 2015 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 510

06/26/2015

Company Report

Pages: 7

Price: 24.95

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 511

06/24/2015

Company Report

Pages: 8

Symphony Health May EXPAREL Sales Estimate Still Light but Within Range of Consensus; Reiterate OUTPERFORM but Reducing PT to $116 for Reduced Growth.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 512

06/24/2015

Company Report

Pages: 8

Symphony Health May EXPAREL Sales Estimate Still Light but Within Range of Consensus; Reiterate OUTPERFORM but Reducing PT to $116 for Reduced Growth.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 513

06/09/2015

Company Report

Pages: 8

Price: 24.95

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 514

06/02/2015

Industry Report

Pages: 43

Emerging Pharmaceuticals - June and 2015 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 515

05/20/2015

Daily Note

Pages: 6

We Believe April EXPAREL Sales Impacted by Price Increase; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 516

05/08/2015

Company Report

Pages: 8

Price: 24.95

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 517

05/04/2015

Industry Report

Pages: 14

May and 2015 Emerging Pharmaceuticals Catalysts

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 518

04/30/2015

Company Report

Pages: 8

Q1 Financials: Top Line Miss Due to Weather; However, Profitability Maintained--Buy On Overdone Weakness; Reiterate OUTPERFORM and $127 Price Target

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 519

04/24/2015

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of April 27th

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 520

04/22/2015

Company Report

Pages: 8

Despite 17% MoM EXPAREL Growth, Symphony Health Estimates a Slight Q1 Miss--We Believe Transient Weather Impact; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party